1. 428 Interim analysis of Phase 2 results for cemiplimab in patients with metastatic basal cell carcinoma (mBCC) who progressed on or are intolerant to hedgehog inhibitors (HHIs). (10th December 2020) Authors: Lewis, Karl; Peris, Ketty; Sekulic, Aleksandar; Stratigos, Alexander; Dunn, Lara; Eroglu, Zeynep; Chang, Anne Lynn; Migden, Michael; Li, Siyu; Mohan, Kosalai; Coates, Ebony; Okoye, Emmanuel; Baurain, Jean-François; Bechter, Oliver; Hauschild, Axel; Butler, Marcus; Hernandez-Aya, Leonel; Licitra, ... Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A260 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗